An In-silico Approach to Design and Validate siRNA against Monkeypox Virus.

INTRODUCTION

The monkeypox virus has emerged as an uncommon zoonotic infection. The recent outbreak of MPXV in Europe and abroad in 2022 presented a major threat to individuals at risk. At present, no specific MPXV vaccinations or medications are available.

METHODS

In this study, we predicted the most effective siRNA against the conserved region of the MPXV and validated the activity by performing molecular docking studies.

RESULTS

Ultimately, the most efficient siRNA molecule was shortlisted against the envelope protein gene (B6R) based on its toxicity, effectivity, thermodynamic stability, molecular interaction, and molecular dynamics simulations (MD) with the Human Argonaute 2 protein.

CONCLUSION

Thus, the strategy may offer a platform for the development of potential antiviral RNA therapeutics that target MPXV at the genomic level.